X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (19) 19
index medicus (16) 16
oncology (16) 16
female (13) 13
cancer (10) 10
article (9) 9
middle aged (9) 9
adult (8) 8
male (8) 8
aged (6) 6
chemotherapy (6) 6
treatment outcome (6) 6
neoplasms - drug therapy (5) 5
therapy (5) 5
united states (5) 5
united states food and drug administration (5) 5
analysis (4) 4
antineoplastic agents - therapeutic use (4) 4
care and treatment (4) 4
clinical trials (4) 4
hydroxamic acids - administration & dosage (4) 4
immunotherapy (4) 4
patients (4) 4
pharmacokinetics (4) 4
pharmacology & pharmacy (4) 4
sulfonamides - administration & dosage (4) 4
trial (4) 4
tumors (4) 4
abridged index medicus (3) 3
adrenal-cortical carcinoma (3) 3
bevacizumab (3) 3
chromatin (3) 3
cisplatin (3) 3
clinical trial results (3) 3
disease-free survival (3) 3
drug approval (3) 3
glucuronosyltransferase - genetics (3) 3
histone deacetylase inhibitors - administration & dosage (3) 3
hydroxamic acids - pharmacokinetics (3) 3
neoplasms - genetics (3) 3
open-label (3) 3
ovarian cancer (3) 3
retrospective studies (3) 3
sulfonamides - pharmacokinetics (3) 3
adjuvant mitotane (2) 2
adrenocortical carcinoma - pathology (2) 2
adrenocortical carcinoma - therapy (2) 2
angiogenesis inhibitors - therapeutic use (2) 2
animals (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents - pharmacokinetics (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
bms-247550 (2) 2
breast-cancer (2) 2
carcinoma (2) 2
cisplatin - administration & dosage (2) 2
clinical pharmacology (2) 2
clinical trials as topic (2) 2
clinical trials as topic - methods (2) 2
combination (2) 2
diagnosis (2) 2
dose-response relationship, drug (2) 2
endocrine care (2) 2
endocrinology & metabolism (2) 2
epothilones - adverse effects (2) 2
etoposide (2) 2
etoposide - administration & dosage (2) 2
fda approval (2) 2
genotype (2) 2
health aspects (2) 2
histone deacetylase inhibitors - pharmacokinetics (2) 2
infusions, intravenous (2) 2
irinotecan-induced neutropenia (2) 2
long-term survival (2) 2
maximum tolerated dose (2) 2
metastasis (2) 2
metastatic melanoma (2) 2
mitotane - therapeutic use (2) 2
models, biological (2) 2
mutation (2) 2
neoplasm staging (2) 2
outcomes (2) 2
ovarian carcinoma (2) 2
ovarian neoplasms - drug therapy (2) 2
pembrolizumab (2) 2
pharmacodynamics (2) 2
phase i (2) 2
phase-ii (2) 2
recurrent (2) 2
risk (2) 2
solid tumors (2) 2
survival analysis (2) 2
thrombocytopenia (2) 2
thymic epithelial tumors (2) 2
ugt1a1-asterisk-28 genotype (2) 2
young adult (2) 2
abdomen, acute - diagnosis (1) 1
active metabolite (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 07/2017, Volume 123, Issue 14, pp. 2604 - 2608
Journal Article
Frontiers in Oncology, ISSN 2234-943X, 2013, Volume 3, pp. 261 - 261
Epigenetic aberrations offer dynamic and reversible targets for cancer therapy; increasingly, alteration via overexpression, mutation, or rearrangement is... 
DNA methylation | Epigenetics | Histone modification | MicroRNA | Small-cell lung cancer | Non-small cell lung cancer | DNA methyltransferase inhibitors | lung carcinogenesis | epigenome | HDAC inhibitors | epigenetic therapy
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2017, Volume 23, Issue 23, pp. 7165 - 7170
Journal Article
The Lancet Oncology, ISSN 1470-2045, 02/2018, Volume 19, Issue 2, pp. 229 - 239
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 9/2018, Volume 82, Issue 3, pp. 565 - 570
Journal Article
Journal Article
Journal Article
Journal Article
The Oncologist, ISSN 1083-7159, 01/2019, Volume 24, Issue 1, pp. 16 - e14
经验教训 • 口服凡德他尼,每日剂量为 300 mg,并在第 1、4、8 和 11 天静脉注射硼替佐米 1.3 mg/m 2 ,可安全给药。 • 在评估 17 例甲状腺髓样癌患者的预后时,研究员认为联合用药比凡德他尼单药更难给药,而且未必会取得更好的疗效。因此,计划中的 II 期研究提前终止。 摘要 背景。 原癌基因... 
CABOZANTINIB | DIAGNOSIS | EFFICACY | AXITINIB | ONCOLOGY | MUTATIONS | COMBINATION | INHIBITOR | CARCINOMA | RET PROTOONCOGENE | CALCITONIN | Clinical Trial Results
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 4_suppl, pp. 427 - 427
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. 10010 - 10010
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2015, Volume 21, Issue 20, pp. 4527 - 4535
The last decade in oncology has been marked by the identification of numerous new potential cancer targets and even more agents designed to inhibit them. The... 
BREAST-CANCER | DOSE-ESCALATION | DESIGN | THERAPY | ONCOLOGY | PHASE-III | APPROVAL | OPEN-LABEL | PERTUZUMAB | Animals | Neoplasms - genetics | Research Personnel | Drug Approval - methods | Genomics | Humans | Drug Discovery - methods | Antineoplastic Agents - pharmacology | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Neoplasms - drug therapy
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2015, Volume 21, Issue 20, pp. 4545 - 4551
In 1962, the passage of the Kefauver-Harris Amendment to the 1938 Food, Drug, and Cosmetic Act required that sponsors seeking approval of new drugs demonstrate... 
ONCOLOGY | CANCER | PEMBROLIZUMAB | Medical Oncology - methods | United States | Humans | Drugs, Investigational - therapeutic use | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic - methods | United States Food and Drug Administration | Neoplasms - drug therapy
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.